Previous published systematic reviews and meta‐analyses regarding the immune‐related risk of pneumonitis have shown that PD1 inhibitors are associated with an increased risk of immune‐related pneumonitis compared with chemotherapy.8, 15, 24 The Bayesian network meta‐analysis in our study allows us to compare the therapeutic regimens indirectly when no head‐to‐head trial existed. This evidence concerns the gene PDCD1 and pneumonitis.